Neoplasia/BPH

	Patients with high-risk features on active surveillance for prostate cancer. Prostate Int Goodman S, Dua Y, Pan HYC, Perera S, Sathianathen N, Perera M, Murphy D, Lawrentschuk N. PMID: 42801144 [PubMed]
	A cfDNA-based DNA methylation classifier for distinguishing prostate cancer from benign prostatic hyperplasia. Prostate Int Lee JH, Oh HJ, Koo HJ, Kim MY, Kim CS, Lim B, Lee JY, Park WY. PMID: 42801083 [PubMed]
	Multicentre evaluation of artificial intelligence risk classification for detection of clinically significant prostate cancer on biparametric MRI. Eur Radiol Guenzel K, Poirot MG, van Loon A, Messina E, Pecoraro M, Panebianco V, Princenthal R, Giganti F. PMID: 42800842 [PubMed - as supplied by publisher]
	A plasma derived hypoxia signature predicts benefit from hypoxia-modifying radiotherapy and reveals dynamic humoral immune modulation in bladder cancer. Br J Cancer Guerrero Quiles C, Abumanhal-Masarweh H, G Abalos J, Lodhi T, Sanchez-Martinez D, Reeves K, James ND, Hall E, Huddart RA, Porta N, Hoskin P, Biolatti LV, Hadjidemetriou M, West CM, Choudhury A. PMID: 42800813 [PubMed - as supplied by publisher]
	Reply to Roberto M. Scarpa's Letter to the Editor re: Paolo Gontero, Richard Perry, Daisy Bridge, et al. Unmet Treatment Need and Challenges Associated with Comparative Evidence Generation in BCG-unresponsive Non-muscle-invasive Bladder Cancer: An Expert Consensus. Eur Urol Oncol 2026;9(3):652-9. Eur Urol Oncol Gontero P, Babjuk M. PMID: 42800742 [PubMed - as supplied by publisher]
	Primary ALK-positive anaplastic large cell lymphoma of the urinary bladder in a pediatric patient: a case report and review of literature. J Hematop Kaur N, Aravind A, Jain SP. PMID: 42799861 [PubMed - indexed for MEDLINE]
	Identification and experimental validation of prognostic genes associated with dietary restriction-related signatures in bladder cancer. Front Immunol Wu X, Sun T, Liu Z. PMID: 42798489 [PubMed - indexed for MEDLINE]
	Repurposing a prostate tumor marker: elevated FPSA/TPSA ratio as a novel non-invasive biomarker for declining eGFR in male type 2 diabetes. Front Endocrinol (Lausanne) Zhao S, Hu H, Zhao X, Zhang L, Niu D. PMID: 42798458 [PubMed - indexed for MEDLINE]
	Plasma exosomal lncRNA SLC16A1-AS1 as an early diagnostic biomarker for renal cell carcinoma. Front Oncol Sun Y, Li Z, Ren C, Wang D, Zhu X. PMID: 42798305 [PubMed]
	Trial design drives outcomes: harmonising efficacy across BCG-unresponsive bladder carcinoma inÂ situ trials. BJU Int Robesti D, Kamat AM, Ploussard G, Contieri R, Fallara G, Briganti A, Montorsi F, van der Heijden AG, Malavaud B, Pohar K, Shore N, Dinney CPN, Martini A. PMID: 42798234 [PubMed - as supplied by publisher]
	Retzius-Sparing Robot-Assisted Radical Prostatectomy: Analysis of Functional and Oncological Outcomes. Medicina (Kaunas) Akdeniz F, Ün S, Boylu U, Köseler A. PMID: 42796398 [PubMed - indexed for MEDLINE]
	Clinical Characteristics and Survival Outcomes of a Clinically Defined Treatment-Emergent Neuroendocrine/Aggressive-Variant Prostate Cancer Phenotype: A Retrospective Study. Medicina (Kaunas) Taban H, Aksoy S, Güven DC, Akta, Y, Aslan F, Erman M. PMID: 42796309 [PubMed - indexed for MEDLINE]
	Prognostic Value of the Modified Glasgow Prognostic Score in Patients with Metastatic Renal Cell Carcinoma Receiving Nivolumab as Second-Line Therapy: A Multicentre Retrospective Cohort Study. Medicina (Kaunas) Biter S, Bayram E, Kö, , Arslan AM, Özalp FR, Sever N, Ünsal A, Altunta, Seyyar M, Dinç G, Büyük, Türker M, Yasl, K, Ayd, Kefeli U, Uzun M, Y, Semiz HS, Erman M, Kara . PMID: 42796282 [PubMed - indexed for MEDLINE]
	The Role of Artificial Intelligence in Optimizing Diagnosis in Prostate Cancer-A Narrative Review. J Clin Med Rahota RG, Badulescu AV, Buhas BA, Moga M, Vaidean D, Popa A, Ploussard G. PMID: 42795960 [PubMed]
	Paired Urinary Cytology and Targeted FGFR3 S249C/R248C Mutation Detection in Urine from Patients with Bladder Cancer: A Pilot Study. J Clin Med Tichil BP, Besleaga A, Gheorghiu I, Chiorean AD, Vica Matei ML, Florea A. PMID: 42795890 [PubMed]
	Predictive Factors for Acute and Late Genitourinary and Gastrointestinal Toxicity Following Modern Radiotherapy for Prostate Cancer: A Narrative Review of Clinical, Dosimetric, Immunological, and Genetic Determinants. Life (Basel) Vadana RN, Maier AC, Dr, Ro, Mitincu-Caramfil SD, Rahnea-Nita RA, Dumitru M, Barzu R, Mihalcia D, Rebegea LF. PMID: 42795342 [PubMed]
	Ultrasound-Activated Microbubbles for Precision Chemo-Radioenhancement in Prostate Cancer: Sonoporation, Therapeutic Synergy, and Translational Pathways. Cancers (Basel) Almasri F, Karshafian R. PMID: 42795033 [PubMed]
	A Multiplex RT-QPCR Assay of ONECUT2, EZH2, and BRCA2 for the Detection of Clinically Significant Prostate Cancer in Needle Biopsies. Cancers (Basel) Inoue Y, Cen SY, Kaneko M, Yuan G, Deng Z, Lu R, Gong MC, Zhang J, Eskenazi F, Konganige S, Aron M, Sekino Y, Iwata T, Fujihara A, Ukimura O, Gill I, Abreu AL, Liang G. PMID: 42794930 [PubMed]
	Lipoprotein(a) and Prostate Cancer: A Systematic Review of Observational, Genetic and Mendelian Randomization Evidence. Int J Mol Sci Kisia, Bajurny W, Karwacki J, Marcinkowska A, Litarski M, Tulski M, Zawadzki D, Patrza, Gurwin A, Nowak , Krajewski W, Szyde, Ma. PMID: 42794701 [PubMed - indexed for MEDLINE]
	Targeting the Androgen Receptor and Associated Cofactors in Prostate Cancer: Novel Approaches and Future Perspectives. Int J Mol Sci Dziuba, Jourdan T, Haendler B. PMID: 42794629 [PubMed - indexed for MEDLINE]

Articles 1 - 20 / 191577

Page 1 of 9579



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy